Jeffrey S. Clark

A Phase II Study of Troglitazone, an Activator of the PPAR?? Receptor, in Patients with Chemotherapy-Resistant Metastatic Colorectal Cancer

Matthew H. Kulke, George D. Demetri, Norman E. Sharpless et al. · The Cancer Journal · 2002 · 149 citations

Medicine, Oncology, Pharmacology +15

Phase II Study of Paclitaxel and Carboplatin for Malignant Melanoma

F. Stephen Hodi, Robert J. Soiffer, Jeffrey S. Clark et al. · American Journal of Clinical Oncology · 2002 · 88 citations

Medicine, Oncology, Pharmacology +14

Species differences in Cl⁻ affinity and in electrogenicity of SLC26A6‐mediated oxalate/Cl⁻ exchange correlate with the distinct human and mouse susceptibilities to nephrolithiasis

Jeffrey S. Clark, David H. Vandorpe, Marina N. Chernova et al. · The Journal of Physiology · 2008 · 83 citations · Full text

Life Sciences, Biochemistry, Nephrology +10

Pharmacological investigation of the mechanisms of platelet-activating factor induced mortality in the mouse

J.M. Young, Patrick J. Maloney, Shizu N. Jubb et al. · Prostaglandins · 1985 · 51 citations

Medicine, Hematology, Pharmacology +8

Increased sulfate uptake by E. coli overexpressing the SLC26-related SulP protein Rv1739c from Mycobacterium tuberculosis

A.S. Zolotarev, Meera Unnikrishnan, Boris E. Shmukler et al. · Comparative Biochemistry and Physiology Part A Molecular & Integrative Physiology · 2007 · 43 citations · Full text

Life Sciences, Microbiology, Molecular Biology +17